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ABSTRACT 
A new four-antigen recombinant immunoblot assay 
(4-RIBA) for confirmation of hepatitis C virus (HCV) 
C-100 enzyme-linked immunosorbent assay (ELISA) 
reactivity was tested in stored serum samples (1984-86) 
of blood donors and recipients and compared with 
results from polymerase chain reaction (PCR) analysis 
of fresh (1990) plasma samples in donors and recip- 
ients from the original study. Of 37 HCV C-100 ELISA- 
positive blood products, 8 were 4-RIBA positive, of 
which 7 were implicated in post-transfusion non-A, 
non-B hepatitis (PT-NANBH) and/or PCR codrmed 
recipient HCV infection. Of 9 recipients with PT- 
NANBH, 8 were reactive in 4-RIBA (6 positive and 2 
indeterminate). With fresh plasma samples, 3 donors 
and 6 recipients who were 4-RIBA positive were also 
PCR positive. 4 4-RIBA indeterminate and 78 4-RIBA 
negative samples of donors and recipients were PCR 
negative. Of 6 4-RIBA positive recipients, 6 were PCR 
positive four to six years later. 1.6% of the 383 recip- 
ients became chronically infected with HCV. The new 
4-RIBA represents a candidate confirmation test to 
discriminate between infective and non-infective 
HCV C-100 ELISA-positive blood donors. 
COMMENTS 
Serological testing for hepatitis C virus (HCV) has 
rapidly emerged from the research laboratory into 
general clinical use (1). The ELISA antibody test using 
an HCV-related antigen, C-100, is limited by a lack of 
sensitivity, particularly early in the infection (1). In one 
study of 15 patients with well-documented posttrans- 
fusion non-A, non-B (NANB) hepatitis, antibody pro- 
duction was delayed for a mean of 21.9 wk. In addition, 
the antibody was not invariably present even in about 
20% of patients who had a firm clinical diagnosis of 
posttransfusion NANB hepatitis (2). Application of the 
polymerase chain reaction (PCR) to sera and liver tissue 
of patients with NANB hepatitis has confirmed the 
presence of viral RNA antedating development of an 
antibody or even in the complete absence of antibody 
development (3). Therefore a negative ELISA anti-HCV 
test cannot be taken as definitive proof that HCV 
infection is absent, particularly early in the illness. 
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A potentially more difficult problem to deal with is a 
patient who is found to be anti-HCV ELISA' when 
clinical liver disease has not been suspected, such as an 
asymptomatic blood donor. Important questions that 
the patient will want answered include whether he or 
she has liver disease and whether he or she is potentially 
infectious to other individuals. The first step in ap- 
proaching such a patient is to consider the possibility of a 
false-positive anti-HCV result, which is always a concern 
in an individual from a population with a low prevalence 
of a condition. A report from Britain has drawn atten- 
tion to the presence of apparently false-positive anti- 
HCV ELISA tests in patients with autoimmune CAH (4). 
It has been felt that the false-positive ELISA result re- 
lates to hypergammaglobulinemia and that anti-HCV 
seropositivity is lost with successful immunosuppressive 
therapy (5). In such cases of suspected autoimmune 
CAH, the clinician should evaluate the patient in the 
routine manner, including performing a liver biopsy. A 
much more difficult challenge is presented by an appar- 
ently well patient with normal liver biochemical tests 
and a positive anti-HCV serological result in the absence 
of confounding factors such as hypergammaglobulin- 
emia. Many patients likely will present in this manner. 
In such a patient who is positive for anti-HCV by 
ELISA, it will be important to confirm that the result is 
truly positive. A number of additional tests have been 
used in the research setting to improve the accuracy of 
anti-HCV testing, notably the recombinant immunoblot 
assay (RIBA) and PCR. An early RIBA test detected 
antibodies to three recombinant antigens: the C-100 also 
present in the ELISA assay; the 5-l-l-polypeptide, a 
product of an overlapping segment of the hepatitis C 
genomes; and superoxide dismutase, which is used to 
enhance efficient expression of proteins in plasmids. 
Experience with this first generation RIBA test indi- 
cated that it tended to be positive in patients whose 
anti-HCV ELISA tests were unequivocally positive with 
a high optical densityht-off ratio. As with any infec- 
tious inoculum, the gold standard of diagnosis is the 
demonstration of infectivity. In this regard, this first 
generation RIBA test appeared to be a good indicator of 
infectivity. Thus researchers have reported (Ebeling F, 
et al. Lancet 1990;335:982-983, Correspondence) that 
all six blood donor samples that were RIBA' were 
implicated in the transmission of posttransfusion hep- 
atitis. Similar information was reported by Garson et al. 
(6) using PCR to evaluate infectivity of donor blood 
units. Thus only one out of six ELISA' units was 
implicated in the transmission of posttransfusion NANB 
hepatitis, and this donor's blood, but not the others, was 
positive for HCV RNA by PCR. 
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Overall, application of the first generation RIBA test 
and PCR can improve the specificity and sensitivity of 
the anti-HCV ELISA test in diagnosing HCV infection. 
It is unlikely, however, that most clinicians will have 
routine access to the technique of PCR through hospital 
laboratories any time in the near future. As described in 
the paper by Van der Poel and colleagues, a newer RIBA 
test, 4-RIBA, has now been developed. Two additional 
HCV recombinant antigens have been added to the 
original panel of HCV antigens. One antigen is from the 
nonstructural NS3 region (C33c), and the other is an 
HCV coreassociated antigen (C22). A positive 4-RIBA 
test is defined as reactivity with two or more of the HCV 
antigens, and an indeterminant result is defined as 
reactivity of one antigen only. In the study by Van der 
Poel and colleagues, this second generation RIBA test 
was validated in a series of anti-HCV ELISA' donors 
and recipients with the additional confirmatory use of 
PCR. 
Four different groups of transfusion recipients were 
studied. Group A included anti-HCV ELISA + recipients 
with a clinical diagnosis of posttransfusion NANB 
hepatitis; group B included ELISA' recipients with no 
clinical evidence of posttransfusion NANB hepatitis; 
group C included recipients of ELISA' blood who had 
not become ELISA' or developed clinical posttrans- 
fusion NANB hepatitis; and group D included recipient 
controls matched for a number of factors, including the 
number of blood products received. Fresh blood samples 
drawn in 1990 were tested by 4-RIBA and PCR, and 
banked sera from the transfusion study period 1984 to 
1986 were tested by ELISA and 4-RIBA. 
Open heart surgery patients (383 transfusion recip- 
ients) received a total of 5,150 blood products prepared 
from 4,906 blood donations of 4,123 blood donors. Of the 
recipients, 86 were identified in groups A, B, C and D, 
and 76 of these were available for follow-up in 1990. 
Thirty-seven blood donations from 30 units were iden- 
tified to be anti-HCV ELISA on retrospective testing 
during this time, and all were retested with 4-RIBA. Of 
these 30 donors, 15 were still donating blood in 1989, 
and all 15 were enrolled in a follow-up study. 
In group A, of the nine recipients found retrospec- 
tively to be anti-HCV ELISA' after transfusion, six 
were 4-RIBA+, two were 4-RIBA-indeterminant and 
one remained negative during the 26 wk after trans- 
fusion. All had been 4-RIBA- before transfusion. On 
follow-up in 1990, five of the eight recipients available 
for study were both 4-RIBA' and PCR' , and three were 
PCR-, of whom two were 4-RIBA- and one was 
indeterminant by 4-RIBA. 
In group B (i.e., individuals who developed anti-HCV 
ELISA seropositivity but no clinical evidence of hepa- 
titis), one individual was 4-RIBA' after transfusion on 
retrospective testing, and the individual on follow-up in 
1990 was both 4-RIBA' and PCR' . All recipients in 
group C (i-e., recipients of ELISA' blood without 
seroconversion or clinical hepatitis), and all group D 
control recipients were negative by 4-RIBA or PCR 
testing. 
With regard to the ELISA' donor units, 8 of 37 were 
4-RIBA+, 3 were indeterminant and 26 were negative. 
Seven of the eight 4-RIBA' blood products were 
implicated in recipient posttransfusion NANB hepatitis, 
HCV infection or both. None of the 4-RIBA- but 
ELISA' specimens were implicated in the transmission 
of hepatitis. Six donors had contributed the eight 
4-RIBA' units, and four of these six donors were 
available for study in 1990. Three of the four were both 
4-RIBA' and PCR'; one donor had become 4-RIBA 
indeterminant after having been positive between 1984 
and 1986 and was PCR- in 1990. 
The 4-RIBA seropositivity tended to persist. Three of 
four 4-RIBA' donors and five of six 4-RIBA' recipients 
in the period 1984 to 1986 were 4-RIBA' and PCR' in 
1990. One recipient who had been 4-RIBA- 
indeterminant in the period 1984 to 1986 but who had 
developed posttransfusion NANB hepatitis had become 
4-RIBA' and PCR' in 1990. 
It would appear from this study that the 4-RIBA test 
is strongly predictive of infectivity of blood for HCV 
because all eight 4-RIBA' blood donor units had been 
implicated in the transmission of NANB hepatitis and/or 
presence of HCV RNA by PCR on follow-up in 1990. The 
remaining 29 4-RIBA- or indeterminant blood products 
were not infective. More widespread use of the 4-RIBA 
test should help determine which ELISA positive pa- 
tients are viremic. Notably, the study draws attention to 
the occurrence of continued viral infection in the 
absence of biochemical evidence of liver dysfunction. 
Thus one recipient who had been classified as having had 
an acute resolved case of posttransfusion NANB hepa- 
titis as assessed by the pattern of serum aminotrans- 
ferase elevations in the period 1984 to 1986 was PCR' 
and 4-RIBA+ in 1990. In addition, three of six PCR' 
recipients had normal serum aminotransferase levels at 
the time of testing in 1990. The authors also comment, 
although they do not provide data to support this, that 
up to 40% of anti-HCV ELISA' blood donors with 
normal ALT levels have chronic hepatitis, based on liver 
histological studies. 
Marcellin and colleagues (7) also reported the use of 
the 4-RIBA test in 100 patients with a clinical diagnosis 
of NANB hepatitis, 76 of whom were anti-HCV ELISA' . 
Ninety-six were 4-RIBA', and two were indeterminant. 
All 76 ELISA' positive patients were 4-RIBA'. This 
study suggests that the 4-RIBA test is not only more 
specific but also more sensitive than the ELISA test. Of 
note is that 18 of the 20 patients in Marcellin's study 
were ELISA- but 4-RIBA' with a positive signal on the 
C33C and C22 bands only. This latter pattern of 
reactivity would also have been sufficient to classify the 
test as positive in Van de Poel's study, with presumably 
the same implication in potential transmission of HCV. 
Future reports about the application of 4-RIBA 
testing will be awaited with interest. It would appear, 
however, that the 4-RIBA test is a useful adjunct in 
determining the significance of anti-HCV ELISA' test 
in blood donors, including those with no clinical and 
biochemical evidence of liver disease. Marcellin's data 
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also suggest that the 4-RIBA test will increase the 
sensitivity of HCV testing generally. Support for this 
view is provided by a report from Ebeling et al (8), 
commenting on Van der Poel’s study. Three of nine 
blood donors’ sera implicated in posttransfusion hepa- 
titis transmission, nonreactive both to the ELISA C-100 
test and to the HCV-related antigens combined in the 
first generation RIBA test, were reactive to the addi- 
tional antigens C33c and C22 in the second generation 
RIBA test. A brief report has also appeared from Italy (9) 
describing a newer ELISA test, HCV C-200 C-22 EIA, 
which uses three HCV antigens instead of one HCV 
antigen, as in the original (2-100 ELISA. In that study, 
61 sera from a series of 420 were anti-HCV’ , 4 3  by both 
C-100 ELISA and C-200 C-22 EIA and 18 by one or other 
test only. All four of the tests positive by C-100 ELISA 
alone were 4-RIBA-. Of the 14 sera positive by C-200 
C-22 EIA but not C-100 ELISA, eight were positive, four 
indeterminate and two were negative on testing by 
confirmatory 4-RIBA. This newer test, as suggested by 
4-RIBA confirmation, is more sensitive and specific than 
relying on C-100 ELISA alone. Addition of further viral 
antigens to RIBA testing may allow even more accurate 
and earlier diagnosis of HCV infection. The significance 
of anti-HCV in an otherwise healthy and biochemically 
normal individual remains uncertain and awaits studies 
of liver biopsy results and observation of the natural 
history of HCV infection in such patients. 
PAUL MARTIN, M.D. 
Jefferson Medical College 











Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo 
Q-L, Kuo G. Detection of antibody to hepatitis C virus in 
prospectively followed transfusion recipients with acute and 
chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494- 
1500. 
Kuo G, Choo Q-L, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, 
Miyamura T. An assay for circulating antibodies to a major 
etiologic virus of human non-A, non-B hepatitis. Science 1989; 
Weiner AJ,  Kuo G, Bradley DW, Borino F, Saracco G, Lee C, 
Rosenblatt J ,  et al. Detection of hepatitis C viral sequences in 
non-A, non-B hepatitis. Lancet 1990;335: 1-3. 
McFarlane IG, Smith HM, Johnson PJ, Bray GP, Vergani D, 
Williams R. Hepatitis C virus antibodies in chronic active 
hepatitis: pathogenetic factor or false-positive result? Lancet 
Czaja AJ, Taswell HF, Rakela J ,  Rabe D. Duration and speci- 
ficity of antibodies to hepatitis C virus in chronic active hepatitis: 
effect of corticosteroid therapy [Abstract]. HEPAT0I.M;Y 1990; 
12:877. 
Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook JA, Trute 
A, Parker D, et al. Detection of hepatitis C viral sequences in blood 
donations by “nested” polymerase chain reaction and prediction of 
infectivity. Lancet 1990;335:1419-1422. 
Marcellin P, Martino-Pergnoy M, Boyer N, Pouteau M, Autmont 
P, Erlinger S, Benhamou J-P. Second generation (RIBA) test in 
diagnosis of chronic hepatitis C. Lancet 1991;337:551-552. 
Ebeling F, Naukkarinen R, Myllyla G, Leikola J .  Second gener- 
ation RIBA to confirm diagnosis of HCV infection. Lancet 
Bassetti D, Cutrupi V, Dallago B, Alfonsi P. Second genera- 





HEPATOCYTE GROWTH FACTOR RECEPTOR AND 
Bottaro DP, Rubin JS,  Faletto DL, Chan AM-L, Kmiecik 
TE, Vande Woude GF, Aaronson SA. Identification of 
the hepatocyte growth factor receptor as the c-met 
proto-oncogene product. Science 1991;251:802-804. 
THE C-MET ONCOGENE 
ABSTRACT 
Hepatocyte growth factor (HGF) is a plas- 
minogen-like protein thought to be a humoral me- 
diator of liver regeneration. A 145-kilodalton tyrosyl 
phosphoprotein observed in rapid response to HGF 
treatment of intact target cells was identified by 
immunoblot analysis as the fl subunit of the c-met 
proto-oncogene product, a membrane-spanning ty- 
rosine kinase. Covalent cross-linking of *261-labeled 
ligand to cellularproteins of appropriate size that were 
recognized by antibodies to c-met directly established 
the c-met product as the cell-surface receptor for HGF. 
COMMENTS 
Hepatocyte growth factor (HGF) is a peptide growth 
factor that stimulates DNA replication of hepatocytes in 
primary culture. The factor was originally purified from 
human rabbit plasma and rat platelets and subsequently 
cloned from various sources including human plasma, 
leukocytes and fibroblast culture medium (1-3). Rat and 
human HGF are synthesized as a precursor that is 
cleaved to a 728 amino acid peptide (1) consisting of two 
disulfide-linked chains of 440 (a subunit) and 233 amino 
acids (p subunit). HGF messenger RNA (mRNA) is 
expressed in many organs (including human liver, 
placenta and leukocytes and rat liver, kidney and 
spleen), and the protein has been detected in various 
tissues including brain, thyroid, intestine and pancreas 
(1, 3, 4). In the liver HGF mRNA is present in 
nonparenchymal cells but apparently not in hepatocytes 
(5). The HGF precursor protein is a plasminogen-like 
molecule (38% homology), but it lacks proteolytic ac- 
tivity. The cx chain of HGF contains four kringle 
structures, whereas plasminogen contains five; the p 
chain has extensive homology with a serine protease 
domain of plasminogen but no proteolytic activity (1). 
Although HGF was originally described as hepatocyte 
specific, it is now clear that HGF stimulates growth of 
many different cell types including melanocytes, kera- 
tinocytes, kidney tubular cells and mammary gland cells 
(6). 
The met gene was originally discovered in 1984 as an 
oncogene present in a human osteogenic sarcoma cell 
line (7, 8). In these cells, the oncogene originated from 
a rearrangement of the c-met protooncogene locus in 
chromosome 7 and the tpr locus in chromosome 1. The 
c-met protooncogene product was characterized and 
found to be a receptor protein with thyrosine kinase 
activity, but no ligand for the receptor was identified. 
The c-met mRNA has been detected in mouse lung, 
brain, kidney, skin and epididymis but apparently not in 
normal liver. Constitutive overexpression of c-met can 
cause transformation and tumorigenesis as shown by 
transfection of the c-met protooncogene under the 
control of the SV-40 promoter into NIH 3T3 cells (7,8). 
